A Multi-Center Randomized, Double-Blind Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli
Latest Information Update: 21 Mar 2022
At a glance
- Drugs LBP EC01 (Primary)
- Indications Escherichia coli infections; Urinary tract infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Locus Biosciences
Most Recent Events
- 24 Feb 2021 Results published in Locus Biosciences Media Release
- 14 Jan 2021 Status changed from active, no longer recruiting to completed.
- 22 Oct 2020 Status changed from recruiting to active, no longer recruiting.